WDP has been shortlisted for the Best Healthcare Analytics Project for the NHS Award, Best Pharmaceutical Partnership with the NHS Award, and Most Impactful Project Addressing Health Inequalities Award at this year’s HSJ Partnership Awards, along with its partners in the Hepatitis C Drug Treatment Services (DTS) Provider Forum.
The HSJ Partnership Awards recognise the outstanding contributions made to healthcare across the UK and showcase these achievements on a national platform.
The Hepatitis C Drug Treatment Services (DTS) Provider Forum has been nominated for its ‘Hepatitis C Virus Screening in Drug Treatment Services’ initiative, which aims to eliminate Hepatitis C from UK drug and alcohol services by the end of 2023.
Membership of the Provider Forum includes a collection of the UK’s leading drug and alcohol service providers and The Hepatitis C Trust. The group’s members have been working together to implement a collaborative reporting and monitoring approach in Hepatitis C test and treat data.
The Hepatitis C Drug Treatment Services (DTS) Provider Forum is praised in the shortlisting for ‘Delivering National Improvements in HCV Screening for Individuals Accessing Drug Treatment Services’, and ‘Engaging the Disengaged in Drug Treatment Services through HCV testing and linkage to care’.
Marlon Freeman, Hep C Coordinator at WDP, said, “We are extremely grateful HSJ has selected The Hep C-Provider Forum to be a finalist in these categories. The hard work from its members is validated and shows appreciation in the mission to micro-eliminate Hep C in drug treatment services.”
The full list of nominees for the 2023 HSJ Partnership awards can be found at partnership.hsj.co.uk/finalists-2023.
This post was originally published by WDP. Read it here.
DDN magazine is a free publication self-funded through advertising.
We are proud to work in partnership with many of the leading charities and treatment providers in the sector.
This content was created by WDP